###begin article-title 0
###xml 79 82 79 82 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 100 102 100 102 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 210 213 210 213 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 218 220 218 220 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 641 644 641 644 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 672 674 672 674 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 995 998 991 994 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1134 1136 1126 1128 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1353 1355 1345 1347 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1394 1397 1386 1389 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1497 1499 1485 1487 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1535 1538 1523 1526 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1697 1699 1685 1687 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1735 1738 1723 1726 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1876 1879 1864 1867 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1889 1891 1877 1879 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 662 666 <span type="species:ncbi:10090">mice</span>
###xml 692 696 <span type="species:ncbi:10090">mice</span>
###xml 1007 1011 <span type="species:ncbi:10090">mice</span>
###xml 1033 1037 <span type="species:ncbi:10090">mice</span>
###xml 1155 1159 <span type="species:ncbi:10090">mice</span>
###xml 1273 1277 <span type="species:ncbi:10090">mice</span>
###xml 1343 1347 <span type="species:ncbi:10090">mice</span>
###xml 1373 1377 <span type="species:ncbi:10090">mice</span>
###xml 1415 1419 <span type="species:ncbi:10090">mice</span>
###xml 1487 1491 <span type="species:ncbi:10090">mice</span>
###xml 1517 1521 <span type="species:ncbi:10090">mice</span>
###xml 1556 1560 <span type="species:ncbi:10090">mice</span>
###xml 1687 1691 <span type="species:ncbi:10090">mice</span>
###xml 1708 1712 <span type="species:ncbi:10090">mice</span>
###xml 1747 1751 <span type="species:ncbi:10090">mice</span>
###xml 1869 1873 <span type="species:ncbi:10090">mice</span>
###xml 1879 1883 <span type="species:ncbi:10090">mice</span>
###xml 1900 1904 <span type="species:ncbi:10090">mice</span>
Prior studies demonstrate that adenosine, acting at one or more of its receptors, mediates the anti-inflammatory effects of methotrexate in animal models of both acute and chronic inflammation. Both adenosine A2A and A3 receptors contribute to the anti-inflammatory effects of methotrexate treatment in the air pouch model of inflammation, and the regulation of inflammation by these two receptors differs at the cellular level. Because different factors may regulate inflammation at different sites we examined the effect of low-dose weekly methotrexate treatment (0.75 mg/kg/week) in a model of acute peritoneal inflammation in adenosine A2A receptor knockout mice and A3 receptor knockout mice and their wild-type littermates. Following intraperitoneal injection of thioglycollate there was no significant difference in the number or type of leukocytes, tumor necrosis factor alpha (TNF-alpha) and IL-10 levels that accumulated in the thioglycollate-induced peritoneal exudates in adenosine A2A knockout mice or wild-type control mice. In contrast, there were more leukocytes, TNF-alpha and IL-10 in the exudates of the adenosine A3 receptor-deficient mice. Low-dose, weekly methotrexate treatment increased the adenosine concentration in the peritoneal exudates of all mice studied, and reduced the leukocyte accumulation in the wild-type mice and A3 receptor knockout mice but not in the A2A receptor knockout mice. Methotrexate reduced exudate levels of TNF-alpha in the wild-type mice and A3 receptor knockout mice but not the A2A receptor knockout mice. More strikingly, IL-10, a critical regulator of peritoneal inflammation, was increased in the methotrexate-treated wild-type mice and A3 knockout mice but decreased in the A2A knockout mice. Dexamethasone, an agent that suppresses inflammation by a different mechanism, was similarly effective in wild-type mice, A2A mice and A3 knockout mice. These findings provide further evidence that adenosine is a potent regulator of inflammation that mediates the anti-inflammatory effects of methotrexate. Moreover, these data provide strong evidence that the anti-inflammatory effects of methotrexate and adenosine are mediated by different receptors in different inflammatory loci, an observation that may explain why inflammatory diseases of some organs but not of other organs respond to methotrexate therapy.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 198 199 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 429 430 429 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 431 432 431 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
Low-dose weekly methotrexate has become the mainstay treatment of rheumatoid arthritis and psoriasis, and it is the gold standard by which other systemic medications are measured in both disorders [1,2]. Methotrexate has been used to treat other inflammatory diseases including ankylosing spondylitis, multiple sclerosis and inflammatory bowel disease, but its efficacy in the therapy of these conditions is far less impressive [3-7].
###end p 4
###begin p 5
###xml 131 132 131 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 183 184 183 184 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 187 189 187 189 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 192 195 192 195 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2B </sub>
###xml 200 201 200 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 273 282 273 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 286 294 286 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 575 577 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 619 622 619 622 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 626 628 626 628 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 796 798 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 916 919 916 919 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 924 926 924 926 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 570 573 <span type="species:ncbi:10116">rat</span>
###xml 591 595 <span type="species:ncbi:10090">mice</span>
###xml 756 762 <span type="species:ncbi:10090">murine</span>
An increasing body of evidence indicates that adenosine mediates, at least in part, the anti-inflammatory effects of methotrexate [8-13]. All known adenosine cell surface receptors (A1, A2A, A2B and A3) contribute to the modulation of inflammation, as demonstrated by many in vitro and in vivo pharmacologic studies (reviewed in [14,15]). We have previously demonstrated pharmacologically, using nonselective antagonists, that the anti-inflammatory effect of methotrexate is mediated by more than one subtype of adenosine receptor in the adjuvant arthritis model in the rat [16], and, using mice rendered deficient in A2A or A3 adenosine receptors, we found that both receptor subtypes are critical for the anti-inflammatory effects of methotrexate in the murine air pouch model of inflammation [17]. Since inflammation at different loci may be regulated by different cellular mechanisms, we determined whether the A2A and A3 receptors played similar roles in regulating inflammation in the peritoneum.
###end p 5
###begin p 6
###xml 326 329 326 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 357 359 357 359 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 493 495 493 495 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 541 544 541 544 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 698 700 694 696 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 807 810 799 802 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 175 180 <span type="species:ncbi:10090">mouse</span>
###xml 319 323 <span type="species:ncbi:10090">mice</span>
###xml 347 351 <span type="species:ncbi:10090">mice</span>
###xml 377 381 <span type="species:ncbi:10090">mice</span>
###xml 527 531 <span type="species:ncbi:10090">mice</span>
###xml 553 557 <span type="species:ncbi:10090">mice</span>
###xml 688 692 <span type="species:ncbi:10090">mice</span>
###xml 709 713 <span type="species:ncbi:10090">mice</span>
###xml 819 823 <span type="species:ncbi:10090">mice</span>
We examined the pharmacologic mechanism by which methotrexate diminishes inflammation in the thioglycollate-induced peritoneal inflammation model of acute inflammation in the mouse. We report here that, similar to the air pouch, methotrexate treatment increases peritoneal exudate adenosine concentrations in wild-type mice, A2A receptor knockout mice and A3 receptor knockout mice but, in contrast to the air pouch model, diminishes leukocyte accumulation only in the peritoneal exudates of A3 receptor knockout and wild-type mice, not of A2A knockout mice. Similarly, methotrexate decreased exudate tumor necrosis factor alpha (TNF-alpha) levels and increased IL-10 levels in wild-type mice and A3 knockout mice, but only marginally decreased TNF-alpha levels and significantly decreased IL-10 levels in A2A knockout mice.
###end p 6
###begin title 7
Materials and methods
###end title 7
###begin title 8
Materials
###end title 8
###begin p 9
Thioglycollate medium (FTG) was obtained from Sigma Chemical Co. (St Louis, MO, USA). Methotrexate was purchased from Immunex (San Juan, PR, USA). All other materials were the highest quality that could be obtained.
###end p 9
###begin title 10
Animals
###end title 10
###begin p 11
###xml 63 66 63 66 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 71 73 71 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 446 448 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 570 580 570 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ad libitum</italic>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 135 139 <span type="species:ncbi:10090">mice</span>
###xml 235 240 <span type="species:ncbi:10090">mouse</span>
###xml 249 253 <span type="species:ncbi:10090">Mice</span>
###xml 325 329 <span type="species:ncbi:10090">mice</span>
###xml 385 390 <span type="species:ncbi:10090">mouse</span>
###xml 451 455 <span type="species:ncbi:10090">Mice</span>
###xml 524 529 <span type="species:ncbi:10090">mouse</span>
Mice with a targeted disruption of the gene for the adenosine A2A and A3 receptor have been described in detail elsewhere [18,19]. The mice used in these experiments were derived from four original heterozygous breeding pairs for each mouse strain. Mice described as wild type were specific for the related receptor knockout mice, since their background was different. Confirmation of mouse genotype was performed by PCR as previously described [17]. Mice were housed in the New York University animal facility, fed regular mouse chow and given access to drinking water ad libitum. All procedures described in the following were reviewed and approved by the Institutional Animal Care and Use Committee of New York University Medical Center and were carried out under the supervision of the facility veterinary staff.
###end p 11
###begin title 12
Peritoneal inflammation
###end title 12
###begin p 13
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 577 579 577 579 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1008 1010 998 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
Animals were given weekly intraperitoneal injections of either methotrexate (0.75 mg/kg, freshly reconstituted lyophilized powder) or vehicle (0.9% saline) for 4 weeks and the experiments were carried out within 3 days of the final dose of methotrexate. Dexamethasone (1.5 mg/kg) was administered by intraperitoneal injection 1 hour prior to induction of inflammation in the peritoneum. Thioglycollate peritonitis was induced by intraperitoneal injection of 0.5 ml sterile solution of thioglycollate medium (10% w/v in PBS) [20]. After 4 hours the animals were sacrificed by CO2 narcosis and their peritoneal cavities were lavaged with 3 ml cold PBS. The peritoneal area was massaged before withdrawing the lavage fluid. Exudates were maintained at 4degreesC until aliquots were diluted 1:1 with methylene blue (0.01% w/v in PBS) and cells were counted in a standard hemocytometer chamber. The concentration of adenosine and TNF-alpha in inflammatory exudates was quantified by HPLC and ELISA, respectively [17]. The IL-10 concentration in cell-free inflammatory exudates was quantified by ELISA (R&D Systems, Minneapolis, MN, USA) following the manufacturer's instructions.
###end p 13
###begin title 14
Statistical analysis
###end title 14
###begin p 15
All statistical analyses were performed by SigmaStat software (SPSS, Inc., Chicago, IL, USA). Differences between groups were analyzed by one-way analysis of variance.
###end p 15
###begin title 16
Results
###end title 16
###begin p 17
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 575 578 575 578 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 616 618 616 618 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 724 727 724 727 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 791 792 791 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 919 921 919 921 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 982 983 982 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 558 562 <span type="species:ncbi:10090">mice</span>
###xml 596 600 <span type="species:ncbi:10090">mice</span>
###xml 636 640 <span type="species:ncbi:10090">mice</span>
###xml 736 740 <span type="species:ncbi:10090">mice</span>
###xml 930 934 <span type="species:ncbi:10090">mice</span>
Since previous studies carried out in our laboratory showed that adenosine receptors play a pivotal role in the formation of the granulation tissue lining the air pouch [21], in a manner that might alter the inflammatory response, we sought to further evaluate the role of adenosine receptors in methotrexate-mediated suppression of inflammation in tissue that had not previously undergone injury or disruption. We therefore determined whether methotrexate inhibits acute leukocyte accumulation in thioglycollate-induced peritoneal inflammation in wild-type mice, adenosine A2A receptor knockout mice and adenosine A3 receptor knockout mice. Similar numbers of leukocytes accumulated in peritoneal inflammatory exudates of A2A knockout mice and their corresponding wild-type controls (Table 1). In contrast, there was a significant increase (20%) in the number of leukocytes that accumulated in peritoneal exudates of A3 knockout mice as compared with the wild-type controls (Table 1).
###end p 17
###begin p 18
###xml 94 97 94 97 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 116 118 116 118 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 139 140 139 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 185 188 185 188 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 217 219 215 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 238 240 236 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 252 254 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 304 307 302 305 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 339 341 335 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 381 383 377 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 395 397 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 420 423 416 419 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 507 509 503 505 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 555 557 549 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 569 571 563 565 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 589 591 583 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 604 606 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 617 619 611 613 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 657 659 649 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 671 673 663 665 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 692 694 684 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 707 709 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 87 91 <span type="species:ncbi:10090">mice</span>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
###xml 198 202 <span type="species:ncbi:10090">mice</span>
###xml 316 320 <span type="species:ncbi:10090">mice</span>
###xml 432 436 <span type="species:ncbi:10090">mice</span>
###xml 527 531 <span type="species:ncbi:10090">mice</span>
###xml 629 633 <span type="species:ncbi:10090">mice</span>
Treatment with methotrexate increased the exudate adenosine concentration in wild-type mice, A2A knockout mice and A3 knockout mice (Table 2) and reduced the leukocyte accumulation in A2A wild-type mice by 30 +/- 5% (P < 0.01 vs control, n = 7; Figure 1a), but reduced the leukocyte accumulation in the A2A knockout mice by only 7 +/- 5% (P = not significant vs wild-type control, n = 6; Figure 1a). In contrast to the A2A knockout mice, methotrexate was no less effective as an anti-inflammatory agent in A3 receptor knockout mice (23 +/- 5% inhibition, P < 0.001 vs A3 knockout control, n = 12; Figure 1b) than in A3 wild-type mice (22 +/- 5% inhibition, P < 0.001 vs A3 wild-type control, n = 10; Figure 1b).
###end p 18
###begin p 19
###xml 85 88 85 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 276 279 276 279 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 296 299 296 299 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 315 317 315 317 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 337 339 337 339 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 413 415 405 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 424 426 416 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 434 436 426 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 448 450 440 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 470 472 462 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 477 479 469 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 484 486 476 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 494 496 486 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 522 523 514 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 97 101 <span type="species:ncbi:10090">mice</span>
###xml 289 293 <span type="species:ncbi:10090">mice</span>
###xml 308 312 <span type="species:ncbi:10090">mice</span>
###xml 327 331 <span type="species:ncbi:10090">mice</span>
###xml 348 352 <span type="species:ncbi:10090">mice</span>
###xml 691 695 <span type="species:ncbi:10090">mice</span>
###xml 708 712 <span type="species:ncbi:10090">mice</span>
To determine whether the diminished anti-inflammatory effect of methotrexate in the A2A knockout mice was specific, we tested the effect of the potent steroidal anti-inflammatory agent dexamethasone in this model. Dexamethasone diminished leukocyte accumulation similarly in A2A wild-type mice, A2A knockout mice, A3 wild-type mice and A3 knockout mice (39 +/- 9%, 38 +/- 13%, 35 +/- 4% and 36 +/- 4% inhibition, P < 0.005, P < 0.05, P < 0.001 and P < 0.001 vs control, n = 4, n = 3, n = 9 and n = 9, respectively; Figure 1). Under the conditions studied there was no difference in the type of white cells that accumulated in the peritoneal cavities of either treated or untreated wild-type mice or knockout mice (>90% polymorphonuclear leukocytes).
###end p 19
###begin p 20
###xml 236 238 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 239 241 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 394 397 386 389 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 493 495 481 483 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 516 517 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 625 627 609 611 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 792 795 772 775 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 816 817 796 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 888 891 868 871 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 896 898 876 878 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 939 941 915 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 384 388 <span type="species:ncbi:10090">mice</span>
###xml 406 410 <span type="species:ncbi:10090">mice</span>
###xml 504 508 <span type="species:ncbi:10090">mice</span>
###xml 615 619 <span type="species:ncbi:10090">mice</span>
###xml 636 640 <span type="species:ncbi:10090">mice</span>
###xml 804 808 <span type="species:ncbi:10090">mice</span>
In general, TNF-alpha accumulation in peritoneal exudates was much lower than previously reported in other models of inflammation, including carrageenan-induced inflammation in the air pouch and zymosan-induced peritoneal inflammation [17,22]. Similar to leukocyte accumulation, we found comparable levels of the proinflammatory cytokine TNF-alpha in peritoneal exudates of wild-type mice and A2A knockout mice, but significantly increased accumulation of TNF-alpha in peritoneal exudates of A3 knockout mice (Table 3). Methotrexate nevertheless inhibited TNF-alpha accumulation in peritoneal exudates of wild-type mice and A3 knockout mice more markedly than leukocyte accumulation (by 67% and 59%, respectively), and had a modest effect on TNF-alpha accumulation in peritoneal exudates of A2A knockout mice (Table 3). These findings are consistent with the prior observation that both A2A and A3 receptors modulate TNF-alpha production [23].
###end p 20
###begin p 21
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 661 663 657 659 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 796 799 792 795 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 820 821 816 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 993 995 989 991 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 1098 1100 1094 1096 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 143 149 <span type="species:ncbi:10090">murine</span>
###xml 346 354 <span type="species:ncbi:9606">patients</span>
###xml 568 572 <span type="species:ncbi:10090">mice</span>
###xml 672 676 <span type="species:ncbi:10090">mice</span>
###xml 786 790 <span type="species:ncbi:10090">mice</span>
###xml 808 812 <span type="species:ncbi:10090">mice</span>
###xml 930 934 <span type="species:ncbi:10090">mice</span>
###xml 1006 1010 <span type="species:ncbi:10090">mice</span>
###xml 1109 1113 <span type="species:ncbi:10090">mice</span>
###xml 1283 1287 <span type="species:ncbi:10090">mice</span>
The cytokine IL-10, released by resident peritoneal macrophages, plays a regulatory anti-inflammatory role in the recruitment of leukocytes in murine models of peritoneal inflammation [22,24]. Since adenosine receptor activation modulates the release of IL-10 by different inflammatory cells [25-27] and methotrexate-treated rheumatoid arthritis patients have shown increased serum levels of this cytokine [28,29], we determined whether constitutively or methotrexate-modified IL-10 accumulation in the inflammatory exudate was altered in adenosine receptor-deficient mice. We found that, similar to the leukocyte infiltration and the TNF-alpha concentration, A3 knockout mice had significantly higher IL-10 levels in their peritoneal inflammatory exudates when compared with wild-type mice and A2A knockout mice (Table 4). As expected, treatment with methotrexate stimulated IL-10 accumulation in the exudate by 56% in wild-type mice, but significantly decreased IL-10 levels in exudates of A2A-deficient mice. Although methotrexate increased IL-10 levels in the exudates of methotrexate-treated A3 knockout mice, this increase did not achieve statistical significance. Due to the high variability in the IL-10 levels we found in our experiments, it would require between 30 and 60 mice per group to achieve statistical significance.
###end p 21
###begin p 22
###xml 230 233 230 233 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 238 240 238 240 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 347 350 347 350 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
These results provide evidence that the anti-inflammatory effects of methotrexate (and adenosine) are mediated by different receptors in different loci. Specifically, in contrast to our previously published observation that both A2A and A3 receptors are required for the anti-inflammatory effects in the air pouch model of inflammation, only the A2A receptor is required to suppress inflammation in the peritoneal space.
###end p 22
###begin title 23
Discussion
###end title 23
###begin p 24
###xml 558 559 557 558 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 562 564 561 563 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 567 569 566 568 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2B</sub>
###xml 576 578 575 577 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 987 989 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
The purine nucleoside adenosine is a ubiquitous autacoid present in all tissues and body fluids. Under basal conditions, the extracellular adenosine concentration is rather constant (30-300 nM), but its concentration can increase dramatically to 10 muM or even higher, as a result of ATP catabolism, when there is an imbalance between energy use and energy supply, such as in oxygen depletion, or when there is cell necrosis as a consequence of mechanical or inflammatory injury. Adenosine acts via four distinct adenosine receptor subtypes - the adenosine A1, A2A, A2B, and A3 receptors - that are all members of the large family of seven-transmembrane spanning, heterotrimeric G protein-associated receptors, coupling to classical second messenger pathways such as modulation of cAMP production or the phospholipase C pathway. In addition, they couple to mitogen-activated protein kinases, which could give them a role in cell growth, survival, death and differentiation (reviewed in [30]).
###end p 24
###begin p 25
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 416 419 416 419 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 424 427 424 427 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2B </sub>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 608 610 608 610 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 710 712 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 713 715 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 761 763 761 763 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 831 839 831 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 840 842 840 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 843 845 843 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 859 862 859 862 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 987 989 987 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 990 992 990 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1010 1013 1010 1013 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2B </sub>
###xml 1166 1168 1166 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1169 1171 1169 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1185 1187 1185 1187 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1307 1309 1307 1309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1310 1312 1310 1312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1313 1315 1313 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1246 1251 <span type="species:ncbi:9606">human</span>
###xml 1276 1282 <span type="species:ncbi:10090">murine</span>
Adenosine is a potent endogenous anti-inflammatory agent, and all four adenosine receptor subtypes participate in this effect (reviewed in [14]). All cell subtypes involved in the inflammatory process differentially express functional adenosine receptors. It is well documented that microvascular endothelial cells, major players conducting the movement of leukocytes between tissue compartments, express adenosine A2A and A2B receptors [31,32]. Pharmacological and molecular approaches have shown that neutrophils, monocytes and macrophages express all four adenosine receptor subtypes. Although adenosine A1 receptor activation has been associated with proinflammatory properties in inflammatory cell types [33-35], the anti-inflammatory effect of selective A1 agonists acting in the central nervous system has been demonstrated in vivo [36-38]. Adenosine A2A receptor activation inhibits neutrophil and monocyte oxidative burst, degranulation and release of cytokines and chemokines [39-41]. Activation of A2B receptors selectively inhibits collagenase mRNA accumulation in synovial fibroblasts and mediates neutrophil-stimulated intestinal epithelial leakiness [42,43]. Adenosine A3 receptors have also been described as anti-inflammatory in human blood leukocytes and in murine models of inflammation [19,44-46].
###end p 25
###begin p 26
###xml 100 102 100 102 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 312 314 312 314 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 560 562 560 562 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 736 738 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 828 830 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 844 846 836 838 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 938 940 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 941 943 933 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 323 327 <span type="species:ncbi:10090">mice</span>
###xml 910 916 <span type="species:ncbi:10090">murine</span>
The results of these reported studies confirm the anti-inflammatory effects of adenosine acting at A3 receptors because animals deficient in this receptor show an exacerbated response to the inflammatory insult. Moreover, we found that more polymorphonuclear leukocytes accumulate in the peritoneal exudates of A3 knockout mice in comparison with their wild-type littermates, consistent with the hypothesis that this receptor plays a greater role as an endogenous regulator of inflammation. Our data are in agreement with prior reports showing that adenosine A3 receptor agonists suppress the expression and production of macrophage inflammatory protein 1alpha, a chemokine that enhances neutrophil recruitment into inflammatory sites [45], and suppress the production of TNF-alpha by lipopolysaccharide-stimulated macrophages [19]. Adenosine A3 receptor agonists thus ameliorate joint inflammation in several murine models of arthritis [45,46].
###end p 26
###begin p 27
###xml 330 332 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 333 335 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 336 338 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 339 341 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 553 556 545 548 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 561 564 553 556 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2B </sub>
###xml 696 699 684 687 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2B </sub>
###xml 743 746 731 734 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 757 759 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 760 762 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 763 765 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 966 969 950 953 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 974 977 958 961 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2B </sub>
###xml 1479 1482 1463 1466 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1487 1490 1471 1474 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2B </sub>
###xml 1654 1656 1638 1640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1657 1659 1641 1643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1660 1662 1644 1646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
Monocytes and macrophages synthesize and release into their environment a variety of cytokines and other proteins that play a central role in the development of acute and chronic inflammation. It has been firmly established that adenosine modulates the production of inflammatory cytokines, including TNF-alpha, IL-10, and IL-12 [23,25-27,47]. In addition to the regulatory effect of adenosine in cytokine secretion, we have further established that Th1 proinflammatory cytokine IL-1 and TNF-alpha treatment increases message and protein expression of A2A and A2B receptors by both microvascular endothelial cells and THP-1 monocytoid cells. IFN-gamma treatment also increased the expression of A2B receptors, but decreased the expression of A2A receptors [25,32,48]. It is therefore probably at inflamed sites, where proinflammatory cytokines such as IL-1 and TNF-alpha are abundantly secreted, mostly by monocytes/macrophages, that the subsequent upregulation of A2A and A2B receptors on endothelial cells and other inflammatory cells along with endogenous adenosine release constitutes a feedback loop to suppress further inflammation. The demonstration that adenosine receptors expressed in microvascular endothelial cells are modified during inflammation suggests an important role for these receptors in the increased angiogenesis and vascular permeability that characterize both acute and chronic inflammatory responses. Moreover, in previous studies, activation of both A2A and A2B receptors on either endothelial cells or macrophages has been reported to enhance the expression of vascular endothelial growth factor and to promote angiogenesis [21,49-51].
###end p 27
###begin p 28
###xml 213 214 213 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 215 216 215 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 990 998 990 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink">de-novo </italic>
###xml 1094 1095 1094 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1096 1098 1096 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1099 1101 1099 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
Methotrexate is an effective disease-modifying drug widely used in low doses at weekly intervals for the control of rheumatoid arthritis and psoriasis with a relatively safe profile compared with other therapies [1,2]. Since folate administration prevents many of the toxicities of methotrexate without affecting the therapeutic effects [52], there is little support for the hypothesis that inhibition of folate-dependent pathways (for example, cellular proliferation) is responsible for the therapeutic effects of the agent. Following administration, methotrexate is taken up by cells and undergoes polyglutamation, resulting in the intracellular accumulation of the long-lived polyglutamates of methotrexate. These metabolites, in addition to inhibiting folate metabolism, directly inhibit 5-aminoimidazole-4-carboxamide ribonucleotide transformylase, resulting in an intracellular accumulation of 5-aminoimidazole-4-carboxamide ribonucleotide, which is an intermediate metabolite in the de-novo pathway of purine synthesis, and has been associated with increases in extracellular adenosine [9,13,53].
###end p 28
###begin p 29
###xml 159 168 159 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 281 289 281 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 525 526 525 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 755 757 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 761 763 761 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 231 236 <span type="species:ncbi:9606">human</span>
###xml 719 727 <span type="species:ncbi:9606">patients</span>
There is now increasing evidence that accumulation of adenosine at sites of inflammation plays a pivotal role in the anti-inflammatory effect of methotrexate. In vitro studies showed that methotrexate produces adenosine release by human fibroblasts and endothelial cells [53], and in vivo studies showed that methotrexate is ineffective in the presence of antagonists of adenosine or adenosine deaminase (the enzyme responsible for the deamination of adenosine to inosine) in animal models of acute and chronic inflammation [8]. Moreover, adenosine receptor antagonists and deletion of adenosine receptors eliminates the anti-inflammatory response to methotrexate in animal models of acute and chronic inflammation and patients with rheumatoid arthritis [13,16,54].
###end p 29
###begin p 30
###xml 274 277 274 277 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 354 355 354 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 744 747 744 747 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 752 754 752 754 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 851 853 851 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 884 887 884 887 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1053 1055 1053 1055 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1133 1136 1129 1132 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1280 1282 1276 1278 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1337 1340 1333 1336 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1458 1461 1454 1457 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1501 1503 1497 1499 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1550 1552 1546 1548 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 1628 1630 1624 1626 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1729 1731 1725 1727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1848 1851 1844 1847 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 1883 1885 1879 1881 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1906 1908 1902 1904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1909 1911 1905 1907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 396 400 <span type="species:ncbi:10116">rats</span>
###xml 1043 1047 <span type="species:ncbi:10090">mice</span>
###xml 1064 1068 <span type="species:ncbi:10090">mice</span>
###xml 1145 1149 <span type="species:ncbi:10090">mice</span>
###xml 1270 1274 <span type="species:ncbi:10090">mice</span>
###xml 1291 1295 <span type="species:ncbi:10090">mice</span>
###xml 1349 1353 <span type="species:ncbi:10090">mice</span>
###xml 1470 1474 <span type="species:ncbi:10090">mice</span>
Although the contribution of adenosine to the mechanism of action of methotrexate is well accepted, it is still unclear which adenosine receptors participate in the effect of methotrexate. Results of early studies, using pharmacological tools, suggested that the adenosine A2A receptor was the main receptor subtype involved in suppressing inflammation [8]. In the model of adjuvant arthritis in rats, however, we found that only nonselective adenosine receptor antagonists could block the protective effect of methotrexate whereas selective antagonists of individual adenosine receptors did not alter the response to methotrexate [16], consistent with involvement of multiple adenosine receptors. Using knockout animals we observed that both A2A and A3 adenosine receptors are involved in methotrexate-mediated suppression of air pouch inflammation [17] but, as reported here, only A2A receptors are involved in methotrexate-mediated suppression of peritoneal inflammation. Methotrexate exerted similar anti-inflammatory effects in wild-type mice and A3 knockout mice, but failed to inhibit leukocyte and TNF-alpha accumulation in A2A knockout mice. Moreover, methotrexate treatment augmented the accumulation of IL-10, a known anti-inflammatory cytokine, in wild-type mice and A3 knockout mice, but actually decreased IL-10 levels in A2A knockout mice. We do not have a clear explanation for this other than to note it is probable that in the MTX-treated A2A knockout mice there is an imbalance in A1 adenosine receptor function in the absence of A2A, consistent with the previous observation of Hasko and colleagues that an A1 adenosine receptor agonist reduces IL-10 release by lipopolysaccharide-stimulated RAW macrophages [27]. IL-10 is therefore, as previously reported, a critical regulator of peritoneal inflammation that is regulated by A2A adenosine receptors but not by A3 adenosine receptors [24,25].
###end p 30
###begin p 31
We infer from these results and previous reports that the involvement of different adenosine receptor subtypes depends upon the site of and stimulus for inflammation. We therefore conclude it is probable that the requirement for activation of multiple adenosine receptor subtypes in the pharmacologic control of chronic inflammation results from the involvement of different types of inflammatory cells and disease-specific differences in the inflammatory environment.
###end p 31
###begin title 32
Conclusion
###end title 32
###begin p 33
###xml 251 254 251 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
The studies reported here provide strong evidence that adenosine mediates the anti-inflammatory effects of methotrexate at doses relevant to those used to treat inflammatory arthritis. These results indicate that agents which interact with adenosine A2A receptors directly or promote adenosine release at inflamed sites may be useful for the treatment of inflammatory conditions, whereas occupancy of other adenosine receptors may be involved in suppression of inflammation in a site-specific fashion.
###end p 33
###begin title 34
Abbreviations
###end title 34
###begin p 35
ELISA = enzyme-linked immunosorbent assay; HPLC, high performance liquid chromatography; IL = interleukin; PBS, phosphate-buffered saline; PCR = polymerase chain reaction; TNF-alpha = tumor necrosis factor alpha.
###end p 35
###begin title 36
Competing interests
###end title 36
###begin p 37
###xml 335 338 335 338 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 378 381 378 381 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
MCM and AD declare that they have no competing interests. BNC declares the following competing interests: consultant - King Pharmaceuticals, Tap Pharmaceuticals, Can-Fite Pharmaceuticals, Bristol-Myers Squibb, Regeneron, Centocor; grant support - NIH, King Pharmaceuticals; honoraria - Merck, Amgen; intellectual property - adenosine A2A receptors for wound healing, adenosine A2A receptor antagonists for fibrosis (both licensed to King Pharmaceuticals).
###end p 37
###begin title 38
Authors' contributions
###end title 38
###begin p 39
MCM designed and coordinated the study, carried out the animal experimental procedures, performed the statistical analysis and drafted the manuscript. AD carried out the adenosine HPLC determinations and the immunoassays. BNC conceived of the study, participated in its design and corrected the manuscript. All authors read and approved the final manuscript.
###end p 39
###begin title 40
Acknowledgements
###end title 40
###begin p 41
This work was supported by grants to BNC from the National Institutes of Health (AR41911, GM56268, AA13336), King Pharmaceuticals, the General Clinical Research Center (M01RR00096) and by the Kaplan Cancer Center. MCM is beneficiary of the Ramon y Cajal program from the Spanish Government (Ministerio de Educacion y Ciencia) and of a grant from the Valencian Government (Conselleria d'Empresa, Universitat i Ciencia)(GV05/031).
###end p 41
###begin article-title 42
Methotrexate and psoriasis in the era of new biologic agents
###end article-title 42
###begin article-title 43
The use of methotrexate in rheumatoid arthritis
###end article-title 43
###begin article-title 44
Methotrexate for ankylosing spondylitis
###end article-title 44
###begin article-title 45
Azathioprine and methotrexate in multiple sclerosis
###end article-title 45
###begin article-title 46
An historical overview of the treatment of Crohn's disease: why do we need biological therapies?
###end article-title 46
###begin article-title 47
Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery
###end article-title 47
###begin article-title 48
Methotrexate in Crohn's disease: long-term efficacy and toxicity
###end article-title 48
###begin article-title 49
###xml 134 141 134 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation
###end article-title 49
###begin article-title 50
Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides
###end article-title 50
###begin article-title 51
Adenosine plasma levels after low dose methotrexate administration
###end article-title 51
###begin article-title 52
The effects of caffeine ingestion on the efficacy of methotrexate [abstract]
###end article-title 52
###begin article-title 53
The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules
###end article-title 53
###begin article-title 54
Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis
###end article-title 54
###begin article-title 55
Role of P1 receptors in inflammation
###end article-title 55
###begin article-title 56
Adenosine: an endogenous regulator of innate immunity
###end article-title 56
###begin article-title 57
###xml 243 246 <span type="species:ncbi:10116">rat</span>
Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine. Evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis
###end article-title 57
###begin article-title 58
Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68
###end article-title 58
###begin article-title 59
###xml 99 103 <span type="species:ncbi:10090">mice</span>
A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice [in process citation]
###end article-title 59
###begin article-title 60
###xml 50 54 <span type="species:ncbi:10090">mice</span>
Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells
###end article-title 60
###begin article-title 61
Kinetics of changes in peritoneal cell populations following acute inflammation
###end article-title 61
###begin article-title 62
Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors
###end article-title 62
###begin article-title 63
Role of resident peritoneal macrophages and mast cells in chemokine production and neutrophil migration in acute inflammation: evidence for an inhibitory loop involving endogenous IL-10
###end article-title 63
###begin article-title 64
Adenosine inhibits IL-12 and TNF-alpha production via adenosine A2a receptor-dependent and independent mechanisms
###end article-title 64
###begin article-title 65
Regulation of macrophage inflammatory protein-1 alpha expression and function by endogenous interleukin-10 in a model of acute inflammation
###end article-title 65
###begin article-title 66
###xml 88 93 <span type="species:ncbi:9606">human</span>
Inflammatory cytokines regulate function and expression of adenosine A(2A) receptors in human monocytic THP-1 cells
###end article-title 66
###begin article-title 67
###xml 38 43 <span type="species:ncbi:9606">human</span>
Adenosine enhances IL-10 secretion by human monocytes
###end article-title 67
###begin article-title 68
###xml 142 146 <span type="species:ncbi:10090">mice</span>
Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice
###end article-title 68
###begin article-title 69
###xml 82 90 <span type="species:ncbi:9606">patients</span>
Circulating interleukin 10 and interleukin-6 serum levels in rheumatoid arthritis patients treated with methotrexate or gold salts: preliminary report
###end article-title 69
###begin article-title 70
Enhanced in vitro induced production of interleukin 10 by peripheral blood mononuclear cells in rheumatoid arthritis is associated with clinical response to methotrexate treatment
###end article-title 70
###begin article-title 71
Signalling from adenosine receptors to mitogen-activated protein kinases
###end article-title 71
###begin article-title 72
###xml 50 55 <span type="species:ncbi:9606">human</span>
Differential expression of adenosine receptors in human endothelial cells: role of A2B receptors in angiogenic factor regulation
###end article-title 72
###begin article-title 73
###xml 86 91 <span type="species:ncbi:9606">human</span>
Th1 cytokines regulate adenosine receptors and their downstream signaling elements in human microvascular endothelial cells
###end article-title 73
###begin article-title 74
###xml 43 48 <span type="species:ncbi:9606">Human</span>
The adenosine/neutrophil paradox resolved. Human neutrophils possess both A1 and A2 receptors which promote chemotaxis and inhibit O2-generation, respectively
###end article-title 74
###begin article-title 75
Fc gamma receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy: A1 receptors are stimulatory and A2 receptors are inhibitory
###end article-title 75
###begin article-title 76
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human mononuclear phagocytes express adenosine A1 receptors. A novel mechanism for differential regulation of Fc gamma receptor function
###end article-title 76
###begin article-title 77
###xml 110 113 <span type="species:ncbi:10116">rat</span>
The effects of (R)-N-(1-methyl-2-phenylethyl) adenosine (L-PIA), a standard A1-selective adenosine agonist on rat acute models of inflammation and neutrophil function
###end article-title 77
###begin article-title 78
###xml 120 124 <span type="species:ncbi:10116">rats</span>
The antiinflammatory effects of adenosine receptor agonists on the carrageenan-induced pleural inflammatory response in rats
###end article-title 78
###begin article-title 79
###xml 46 50 <span type="species:ncbi:10116">rats</span>
Spinal cord adenosine receptor stimulation in rats inhibits peripheral neutrophil accumulation. The role of N-methyl-D-aspartate receptors
###end article-title 79
###begin article-title 80
###xml 71 76 <span type="species:ncbi:9606">human</span>
Adenosine: a physiological modulator of superoxide anion generation by human neutrophils
###end article-title 80
###begin article-title 81
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 90 95 <span type="species:ncbi:9606">human</span>
Engagement of adenosine receptors inhibits hydrogen peroxide (H2O2-) release by activated human neutrophils
###end article-title 81
###begin article-title 82
###xml 78 83 <span type="species:ncbi:9606">human</span>
Differential regulatory effects of adenosine on cytokine release by activated human monocytes
###end article-title 82
###begin article-title 83
Mechanisms of methotrexate action in rheumatoid arthritis. Selective decrease in synovial collagenase gene expression
###end article-title 83
###begin article-title 84
Neutrophil-derived 5' -adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation
###end article-title 84
###begin article-title 85
###xml 57 62 <span type="species:ncbi:9606">human</span>
Adenosine inhibits neutrophil degranulation in activated human whole blood; involvement of adenosine A2 and A3 receptors
###end article-title 85
###begin article-title 86
Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists
###end article-title 86
###begin article-title 87
###xml 61 67 <span type="species:ncbi:10090">murine</span>
Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models
###end article-title 87
###begin article-title 88
###xml 14 19 <span type="species:ncbi:9606">human</span>
Inhibition of human monocyte TNF production by adenosine receptor agonists
###end article-title 88
###begin article-title 89
IFN-gamma up-regulates the A2B adenosine receptor expression in macrophages: a mechanism of macrophage deactivation
###end article-title 89
###begin article-title 90
###xml 78 84 <span type="species:ncbi:10090">murine</span>
Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin
###end article-title 90
###begin article-title 91
Adenosine A2A receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis
###end article-title 91
###begin article-title 92
Adenosine A2A receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin 1
###end article-title 92
###begin article-title 93
Folate supplementation and methotrexate
###end article-title 93
###begin article-title 94
Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells
###end article-title 94
###begin article-title 95
Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis
###end article-title 95
###begin title 96
Figures and Tables
###end title 96
###begin p 97
###xml 109 113 109 113 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 114 117 114 117 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 137 140 137 140 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 166 170 166 170 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 171 173 171 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 193 195 193 195 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 629 631 627 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 666 668 664 666 <sup xmlns:xlink="http://www.w3.org/1999/xlink">++</sup>
###xml 668 670 666 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 704 705 702 703 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 705 707 703 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 785 787 783 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 103 107 <span type="species:ncbi:10090">mice</span>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
###xml 158 162 <span type="species:ncbi:10090">mice</span>
###xml 183 187 <span type="species:ncbi:10090">mice</span>
###xml 213 217 <span type="species:ncbi:10090">mice</span>
###xml 660 664 <span type="species:ncbi:10090">mice</span>
###xml 698 702 <span type="species:ncbi:10090">mice</span>
###xml 734 738 <span type="species:ncbi:10090">mice</span>
Effect of methotrexate and dexamethasone treatment on leukocyte accumulation in peritoneal exudates of mice. (a) A2A wild-type mice and A2A receptor knockout mice or (b) A3 wild-type mice and A3 receptor knockout mice either were treated with weekly injections of methotrexate (0.75 mg/kg) or saline control for 4 weeks prior to induction of inflammation or were treated with a single intraperitoneal injection of dexamethasone (1.5 mg/kg) or saline 1 hour before induction of inflammation and subsequent collection of inflammatory exudates, as described. Results are presented as the mean (+/- SEM) million cells per exudate. **P < 0.001 vs wild-type control mice, ++P < 0.001 vs knockout control mice, +P < 0.05 vs knockout control mice, all one-way analysis of variance (Bonferroni t test).
###end p 97
###begin p 98
Leukocyte accumulation in inflammatory exudates
###end p 98
###begin p 99
###xml 441 443 441 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 455 457 455 457 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 483 485 483 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
###xml 195 199 <span type="species:ncbi:10090">mice</span>
###xml 388 392 <span type="species:ncbi:10090">mice</span>
###xml 416 420 <span type="species:ncbi:10090">mice</span>
###xml 434 438 <span type="species:ncbi:10090">mice</span>
###xml 467 471 <span type="species:ncbi:10090">mice</span>
Inflammatory exudates were induced in the peritoneum of knockout and wild-type mice, as described. After 4 hours the exudates were collected and the leukocytes quantitated. The wild-type control mice were derived from the same heterozygous breeding pairs and were matched for age and sex. There was no difference in the number of leukocytes accumulating in the exudates of male vs female mice in either the knockout mice or wild-type mice. *P < 0.005 vs A3 wild-type mice, Student's t test.
###end p 99
###begin p 100
Adenosine concentration in peritoneal exudates
###end p 100
###begin p 101
###xml 17 20 17 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 47 49 47 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 425 427 425 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 473 475 473 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 483 485 483 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 498 501 498 501 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 534 536 534 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 542 549 542 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224; </sup>
###xml 549 551 544 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 564 566 559 561 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 599 601 594 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 38 42 <span type="species:ncbi:10090">mice</span>
###xml 67 71 <span type="species:ncbi:10090">mice</span>
###xml 266 270 <span type="species:ncbi:10090">mice</span>
###xml 409 414 <span type="species:ncbi:10090">mouse</span>
###xml 457 461 <span type="species:ncbi:10090">mice</span>
###xml 518 522 <span type="species:ncbi:10090">mice</span>
###xml 583 587 <span type="species:ncbi:10090">mice</span>
Wild-type mice, A2A receptor knockout mice or A3 receptor knockout mice were treated with either weekly injections of methotrexate (0.75 mg/kg) or saline control for 4 weeks prior to induction of inflammation. Inflammatory exudates were induced in the peritoneum of mice, as described. After 4 hours the exudates were collected and the adenosine levels quantitated. Wild-type data are a combination from both mouse strains. *P < 0.0001 vs wild-type control mice, Student's t test; **P < 0.0001 vs A2A knockout control mice, Student's t test; dagger P < 0.0001 vs A3 knockout control mice, Student's t test.
###end p 101
###begin p 102
Tumor necrosis factor alpha concentration in peritoneal exudates
###end p 102
###begin p 103
###xml 17 20 17 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 47 49 47 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 492 494 492 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 539 541 539 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 548 550 548 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 594 596 594 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 602 608 602 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;</sup>
###xml 608 610 603 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 621 623 616 618 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 656 658 651 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 38 42 <span type="species:ncbi:10090">mice</span>
###xml 67 71 <span type="species:ncbi:10090">mice</span>
###xml 266 270 <span type="species:ncbi:10090">mice</span>
###xml 475 480 <span type="species:ncbi:10090">mouse</span>
###xml 523 527 <span type="species:ncbi:10090">mice</span>
###xml 578 582 <span type="species:ncbi:10090">mice</span>
###xml 640 644 <span type="species:ncbi:10090">mice</span>
Wild-type mice, A2A receptor knockout mice or A3 receptor knockout mice were treated with either weekly injections of methotrexate (0.75 mg/kg) or saline control for 4 weeks prior to induction of inflammation. Inflammatory exudates were induced in the peritoneum of mice, as described. After 4 hours the exudates were collected, centrifuged at 100 x g and frozen. Tumor necrosis factor alpha levels were later quantitated by ELISA. Wild-type data are a combination from both mouse strains. **P < 0.001 vs wild-type control mice, Student's t test; *P < 0.05 vs wild-type control mice, Student's t test; daggerP < 0.05 vs A3 knockout control mice, Student's t test.
###end p 103
###begin p 104
IL-10 concentration in peritoneal exudates
###end p 104
###begin p 105
###xml 17 20 17 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 47 49 47 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 471 473 471 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 518 520 518 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 528 530 528 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 574 576 574 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 582 588 582 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;</sup>
###xml 588 590 583 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 601 604 596 599 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A </sub>
###xml 637 639 632 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 38 42 <span type="species:ncbi:10090">mice</span>
###xml 67 71 <span type="species:ncbi:10090">mice</span>
###xml 266 270 <span type="species:ncbi:10090">mice</span>
###xml 453 458 <span type="species:ncbi:10090">mouse</span>
###xml 502 506 <span type="species:ncbi:10090">mice</span>
###xml 558 562 <span type="species:ncbi:10090">mice</span>
###xml 621 625 <span type="species:ncbi:10090">mice</span>
Wild-type mice, A2A receptor knockout mice or A3 receptor knockout mice were treated with either weekly injections of methotrexate (0.75 mg/kg) or saline control for 4 weeks prior to induction of inflammation. Inflammatory exudates were induced in the peritoneum of mice, as described. After 4 hours the exudates were collected, centrifuged at 100 x g and frozen. IL-10 levels were later quantitated by ELISA. Wild-type data are a combination from both mouse strains. ** P < 0.001 vs wild-type control mice, Student's t test; * P < 0.05 vs wild-type control mice, Student's t test; daggerP < 0.05 vs A2A knockout control mice, Student's t test.
###end p 105

